Gemphire Therapeutics Profile

6.66
USD 0.29  4.17%
10%
51%

Purchase by Seth Reno of 14286 shares of Gemphire Therapeutics

Gemphire Therapeutics Inc insider trading alert for perchase of common stock by Seth Reno, Chief Commercial Officer, on February 12, 2018. This event was filed by Gemphire Therapeutics Inc with SEC on 2018-02-12. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Gemphire Therapeutics Summary

Gemphire Therapeutics Inc (GEMP) is traded on BATS Exchange in USA. It is located in MICHIGAN, U.S.A and employs 17 people. Gemphire Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 95.74 M. Gemphire Therapeutics Inc has 13.78 M outstanding shares of which 577.3 K shares are currently shorted by private and institutional investors with about 16.0 trading days to cover. Gemphire Therapeutics Inc. currently holds about 25.34 M in cash with (23.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38.
Check Gemphire Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Gemphire Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Gemphire Therapeutics Against Markets

Current Ratings

Gemphire Therapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 20% 
Equity ratings for Gemphire Therapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver diseasenon-alcoholic steatohepatitis . It is developing gemcabene , an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. Gemphire Therapeutics is traded on BATS Exchange in USA. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameGemphire Therapeutics Inc
President CEOMina SoochAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
LocationMICHIGAN, U.S.A
Business Address17199 North Laurel Park Drive
ExchangeBATS Exchange
CUSIP36870A108
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.gemphire.com
Contact Number248 681 9815
CurrencyUSD - US Dollar

Recommendations

Gemphire Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
24.5Strong Buy4Odds
Gemphire Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Gemphire Therapeutics Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Gemphire Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.72March 21, 2018
Gemphire Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Gemphire Therapeutics Corporate Directors
Kenneth Kousky Independent Director
Andrew Sassine Independent Director, MBA
Pedro Lichtinger Independent Director, MBA